An Open-Label, Single-Dose, Randomized, Crossover Study to Compare the Bioavailability of the Intranasal Administration of 20 mg OPTINOSE SUMATRIPTAN With 20 mg IMITREX (Sumatriptan) Nasal Spray, 100 mg IMITREX (Sumatriptan) Oral Tablet and 6 mg IMITREX (Sumatriptan) Subcutaneous Injection in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2013
At a glance
- Drugs Sumatriptan (Primary) ; Sumatriptan (Primary) ; Sumatriptan (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- 28 Jun 2013 Results presented at the 2013 International Headache Congress, according to an Optinose media release.
- 02 Oct 2012 Results have been reported in an OptiNose media release.
- 28 Feb 2012 Actual patients number is 20 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History